Related Experiment Video
Updated: Aug 29, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
miR-1294 Upregulation as a Diagnostic Biomarker for Cholangiocarcinoma
Kittiya Supradit1, Teva Phanaksri2, Sattrachai Prasopdee2,3,4
1Department of Radiological Technology, Faculty of Science, Ramkhamhaeng University, Bangkok, 10240, Thailand.
Objective:
To investigate plasma miR-1294 levels in cholangiocarcinoma (CCA) patients compared with healthy individuals and Opisthorchis viverrini-infected subjects.
Methods:
To assess its potential as a plasma-based diagnostic biomarker, plasma samples were collected and total RNA was extracted from 15 healthy controls (HC), 12 O. viverrini (OV)-infected individuals, and 33 patients with CCA. miR-1294 expression was quantified using RT-qPCR (MiRXES).
Results:
Relative expression analysis demonstrated a significant upregulation of plasma miR-1294 in patients with CCA compared with both HC and OV groups (P < 0.0001). Receiver operating characteristic (ROC) curve analysis showed that miR-1294 discriminated CCA from non-CCA subjects, yielding an area under the curve (AUC) of 0.8676, with a specificity of 96.30% and a sensitivity of 63.64%.
Conclusion:
The upregulation of plasma miR-1294 was investigated in this study. Despite these promising findings, the moderate sensitivity suggests that miR-1294 alone may not be sufficient as a standalone diagnostic marker. Nevertheless, its high specificity and non-invasive detectability highlight its potential utility as a complementary biomarker, particularly in combination with other diagnostic indicators for improved detection of CCA.